Clinical Trial Update: A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating single-agent eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer has completed, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Locally Recurrent Breast Cancer

Drugs mentioned

• ERIBULIN MESYLATE (Eribulin mesylate)

Snippet

Sponsor: Eisai Inc. | Conditions: Locally Recurrent, Metastatic Breast Cancer ( HER2 Negative) | Phase 2 | Status: COMPLETED | Results posted: 2016-08-09